New Delhi: India reported 13,405 fresh covid cases in past 24 hours. As per the Ministry of Health and Family Welfare, the number of active cases has fallen below two lakh after 49 days.
The daily positivity rate was at 1.93 per cent. India’s Covid recovery tally increased to 4,21,24,284 with 37,901 recoveries in 24 hours prior to yesterday’s update.
The daily COVID-19 cases have remained below one lakh for 16 consecutive days.
The active cases declined to 1,81,075 comprising 0.42 per cent of the total infections, while the national COVID-19 recovery rate has further improved to 98.38 per cent.
Regular international flights are likely to resume from March 15 and will follow the standard operating procedures effective at Indian airports for foreign arrivals and departure, government NDTV sources said on Monday.
Given the consistent decline in Covid cases, a decision on resuming scheduled international flights has almost been arrived at by the Civil Aviation Ministry following consultation with the Health Ministry, they said.
However, no official announcement has been made by the Directorate General of Civil Aviation so far.
“Regular International flights is likely to resume from March 15. The Guidelines for International Arrivals, which came into effect from February 14, will be followed at airports for the passengers of these flights,” an official source said.
A second COVID-19 vaccine for children has received emergency use authorisation in India. Biological E Ltd’s Corbevax has got EUA for children and teens between 12 and 18 years, the vaccine-maker said in a statement today.
Till now India has been administering Bharat Biotech’s Covaxin to teens between 15 and 18 years old since January 3.
The EUA, short for emergency use authorisation, for Corbevax’s restricted use in emergency among adults was cleared by the regulator Drugs Controller General of India in December 2019.
“BE received the approval for restricted use in an emergency situation in adolescents aged 12 to 18 years based on interim results (of the ongoing phase II/III clinical study),” Biological E said in the statement today.
Corbevax is being billed as India’s first homegrown “receptor-binding domain protein sub-unit vaccine against COVID-19”. A receptor-binding domain is a key part of a virus located on its “spike” domain that allows it to dock to body receptors to enter and infect cells. These are also the primary targets in the prevention and treatment of viral infections.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
